Read CURRICULUM VITAE text version

CURRICULUM VITAE Sally F. Alrabaa, MD

MAILING ADDRESS: 1 Tampa General Circle Tampa, FL 33606 COMMUNICATION: Office: Fax: E-mail: (813) 844-4174 (813) 844-7605 [email protected]

EDUCATION: University of Khartoum, Sudan, AS, 1991 University of Khartoum, Sudan, MBBS, 1996 POSTGRADUATE TRAINING: Fellow, Division of Infectious Disease and International Medicine University of South Florida, College of Medicine, Tampa, Florida, 2008-2010 Resident, Department of Internal Medicine Saint Vincent's Medical Center, Staten Island, New York, 2001-2004 House officer, Department of Internal Medicine Khartoum Teaching Hospital, Khartoum, Sudan, 1996-1999 HONORS AND AWARDS: Alpha Omega Alpha, University of South Florida College of Medicine, Tampa, Florida Bodine Award ­ Saint Vincent's Medical Center (End of residency award for medical excellence and exemplary patient care/concern, Staten Island New York) University Award ­ Biochemistry, University of Khartoum, Sudan University Award ­ Pediatrics, University of Khartoum, Sudan University Awards ­ Internal Medicine, University of Khartoum, Sudan

1

BOARD CERTIFICATION: American Board of Internal Medicine American Board of Infectious Diseases STATE LICENSES: Florida, #ME 101203 MEMBERSHIP: American College of Physicians Faculty member, Florida/Caribbean AIDS Education Training Center Member of the International Society for Infectious Diseases ACADEMIC POSITIONS AND WORK EXPERIENCE: Assistant Professor of Internal Medicine, University of South Florida College of Medicine, Division of Infectious Disease and International Medicine, Tampa, 2010Present. Infectious Disease Consultant, Tampa General Hospital, 2010- Present Staff Physician, Hillsborough County Health Department, Tampa, Florida, 2010present. Teaching Faculty, Florida Caribbean AIDS Education and Training Center, 2010Present Internist, Saint Mary's/Duluth Clinic, 10/2004 ­ 4/2008 Faculty, University of Khartoum, Faculty of Medicine, 11/1996 ­ 8/1999 Internist, Khartoum Teaching Hospital, 11/1996-8/1999 RESEARCH EXPERIENCE: H. Lee Moffitt Cancer Center, Tampa 11/2010 · S Alrabaa, J Greene. Interferon gamma in the treatment of disseminated mycobacterium abscesses infection in leukemic patients

2

H. Lee Moffitt Cancer Center, Tampa 1/2009 ­ 10/2009 · Abstract presented at IDSA Meeting, 10/2009 · S Alrabaa, J Greene. Alpha interferon in the treatment of RSV pneumonia in bone marrow transplant recipients; improved morbidity and mortality H. Lee Moffitt Cancer Center, Tampa 9/2008 ­ 12/2008 · Abstract presented at IDSA Meeting, 10/2009 · S Alrabaa, J Greene. Fluoroquinolone resistance among leukemic patients receiving fluoroquinolone prophylaxis; increased incidence but improved overall morbidity Saint Vincent's Medical Center · Case studies, Dr. Susan Grossman · TTP as a complication of TNF-alpha therapy. · Case presented at ACP Conference, 2003 8/2002 ­ 4/2003

Saint Vincent's Medical Center 7/2002 ­ 6/2003 · Research during residency, · S Alrabaa, D Bloomfield. Incidence of right colonic polyps and use of sigmoidoscopies Saint Vincent's Medical Center 4/2002 ­ 6/2004 · Research; residents' knowledge in end of life care, S Alrabaa, S Grossman and C Wong Omdurman Teaching Hospital 10/1994 ­ 10/1995 · S Alrabaa, A Toum. Retrospective study to determine perinatal mortality incidence and causes in a maternity hospital in Sudan OTHER RESEARCH: Current Studies ­ Sub- Investigator: (Location for all of the following research activities: USF/Hillsborough County Health Department) DAIDS-START PI: Somboonwit C 2009-Present Strategically Timing of Antiretroviral Therapy. CPCRA START (Funded: 200,400) Schering- P04875 (A673DL) PI: Somboonwit C 2009-Present Efficacy and Safety of Vicriviroc in HIV-Infected Treatment Naive Subjects (Funded: 239,173) Merck-IISP 33107 (A673CG) PI: Somboonwit C 2008-Present A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir versus NRTIs as a Backbone in HIV-Infected Patients Switched from a Stable Boosted PI Regimen (Funded: 74,561)

3

Gilead (GS-US-236-0102) PI: Wills T 2010-present A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults Gilead (GS-US-236-0103) PI: Wills T 2010-present A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir- Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults Gilead (GS-US-236-0124) PI: Wills T 2010-present A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of GS-9350 Boosted Atazanavir Versus Ritonavir=Boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults Tibotec (TMC278-209) PI: Casanas B 2008-present A Phase III, Randomized, Double-Blind Study of TMC278 25 mg once daily in Combination with a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive HIV-1 Infected Subjects Gilead (GS-US-183-0130) PI: Wills T 2008-Present A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults PUBLICATIONS/PRESENTATIONS/POSTER SESSIONS: Pham T, Alrabaa S, Somboonwit C, Hung L, Montero J. The HIV virologic outcomes of different interventions among treatment-experienced patients with 2 consecutive detectable low-level viremia. J Int Assoc Physicians AIDS Care (Chic). 2011 Jan-Feb; 10(1):54-6. University of South Florida, College of Medicine, Tampa, FL, USA; Found at: www.ncbi.nlm.nih.gov/pubmed/21368016 Alrabaa S, Greene J. Alpha interferon in the treatment of RSV pneumonia in bone marrow transplant recipients, improved morbidity and mortality. Presented at: Infectious Disease Society of America (IDSA) Annual Meeting, Oct. 2009, Philadelphia, PA Alrabaa S, Greene J. Fluoroquinolone resistance among leukemic patients receiving fluoroquinolone prophylaxis, increased incidence but improved overall morbidity, IDSA Annual Meeting, Oct 2009, Philadelphia, PA

4

Wills T, Sinnott JT, Alrabaa S. Viral Hemorrhagic Fevers. APIC Text of Infection Control and Epidemiology, 3rd ed. Association for Professionals in Infection Control and Applied Epidemiology Principles and Practice (APIC). Washington, 2009 Alrabaa S, Grossman S, Wong C. Residents' experience and training in end of life care, American Journal of Palliative Medicine, 5/2003 Alrabaa S, TTP and TNF @ therapy, ACP, 4/2003 VOLUNTEER ACTIVITY: Rosaris Community, Southwest Sudan 5/1991 ­ 5/1996 Volunteer Medical Student (under the direction of Dr. M. Altoum and associated with the Community Medicine and Public Health Department Outreach) · Identify patients with leprosy and offer free treatment/care · Develop and conduct health education for community women and children

5

Information

CURRICULUM VITAE

5 pages

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

425525